Compare Stocks → Only a fool would buy Nvidia today… (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNYSE:AMTOTCMKTS:CHEOF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$10.28+15.6%$9.92$2.09▼$14.84$552.34M0.086.02 million shs5.85 million shsAMTAmerican Tower$196.05-0.7%$196.36$154.58▼$219.10$91.43B0.682.31 million shs722,145 shsCHEOFCochlear$223.46+0.7%$213.72$145.73▼$230.46N/AN/A172 shs4 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+2.77%-4.82%-21.47%-23.49%+101.13%AMTAmerican Tower+1.70%+1.42%+5.16%-9.11%+2.35%CHEOFCochlear+0.68%-0.02%+1.57%+12.57%+50.76%Only a fool would buy Nvidia today… (Ad)Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.In this new presentation – which Porter Stansberry details why this company could be the linchpin ofMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.3096 of 5 stars3.42.00.00.02.21.70.0AMTAmerican Tower4.6881 of 5 stars2.54.03.33.13.32.51.3CHEOFCochlearN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.75Moderate Buy$15.7553.21% UpsideAMTAmerican Tower2.91Moderate Buy$217.5510.96% UpsideCHEOFCochlearN/AN/AN/AN/ACurrent Analyst RatingsLatest CHEOF, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/5/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$224.00 ➝ $234.002/28/2024AMTAmerican TowerBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$235.00 ➝ $228.002/28/2024AMTAmerican TowerJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$236.00 ➝ $230.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.001/24/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$229.00 ➝ $224.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$4.41M125.25N/AN/A$3.77 per share2.73AMTAmerican Tower$11.14B8.20$10.01 per share19.59$23.30 per share8.41CHEOFCochlearN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$84.71M-$1.54N/AN/AN/AN/A-46.81%-42.23%5/9/2024 (Estimated)AMTAmerican Tower$1.48B$3.1861.6518.601.3413.31%12.80%2.24%4/24/2024 (Estimated)CHEOFCochlearN/A$1.64136.09∞N/AN/AN/AN/AN/ALatest CHEOF, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/202412/31/2023AMTAmerican Tower$2.10$0.94-$1.16$0.18$2.74 billion$2.79 billion DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.803.47%+12.50%213.84%12 YearsCHEOFCochlear$1.270.57%N/A77.34%N/ALatest CHEOF, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/14/2024AMTAmerican Towerquarterly$1.623.3%4/11/20244/12/20244/26/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A12.8912.89AMTAmerican Tower3.290.690.69CHEOFCochlearN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%CHEOFCochlear22.47%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.24%CHEOFCochlearN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5253.73 million51.53 millionOptionableAMTAmerican Tower5,643466.35 million465.23 millionOptionableCHEOFCochlear4,800N/AN/ANot OptionableCHEOF, ADR, AMT, and ALT HeadlinesSourceHeadlineCochlear (OTCMKTS:CHEOF) Trading Up 0.9%americanbankingnews.com - March 27 at 1:00 AMAnalysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Cochlear Limited (OtherCHEOF)markets.businessinsider.com - July 26 at 8:16 AMAfter long gap, Kerala govt approves funds to upgrade cochlear implant devicesnewindianexpress.com - July 24 at 7:57 AMCochlear implant for children: Kerala government sanctions Rs 59.47 lakhsenglish.mathrubhumi.com - July 24 at 7:57 AMA tribute to Oommen Chandy: Congress to help 50 hearing-impaired childrenonmanorama.com - July 23 at 3:32 PMFunds allocated for upgrade of cochlear implants of 25 childrenthehindu.com - July 23 at 10:32 AMHow Oommen Chandy heard a widow out and launched cochlear implant scheme when he became CMonmanorama.com - July 20 at 12:37 AMChandy’s Cochlear Implant Scheme hits hurdles, parents seek government helpmsn.com - July 20 at 12:37 AMSensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europebenzinga.com - July 19 at 9:36 AM7-year-old girl hears for first time after Chhattisgarh govt sponsors operation, father wants her to become doctormsn.com - July 18 at 1:15 PMOommen Chandy: Humane leader who put patients first, say health expertsmsn.com - July 18 at 8:15 AMMinerva mentors giving stars a sporting chancetheaustralian.com.au - July 17 at 10:18 AMOver Rs 86 crore spent from Maharashtra CM medical relief funduniindia.com - July 14 at 12:50 PMTownsville University Hospital audiology review finds failures with testing, cochlear implantsabc.net.au - July 13 at 10:40 AM‘Urgent’ treatment needed for children after Townsville University Hospital audiology failurestownsvillebulletin.com.au - July 12 at 11:21 PMMaureen able to listen to Slim Dusty thanks to life changing cochlear implantsheppnews.com.au - July 11 at 8:01 PMSensorion submits clinical trial application with UK MHRA for lead gene therapy candidate OTOF-GTpharmabiz.com - July 11 at 10:00 AMMorgan Stanley Keeps Their Hold Rating on Cochlear Limited (CHEOF)markets.businessinsider.com - July 10 at 11:30 PMSensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UKbenzinga.com - July 10 at 8:29 AMBIRRD to conduct 25 cochlear implant surgeries a monththehansindia.com - July 8 at 12:25 AMSensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Studybenzinga.com - July 5 at 5:49 AMBPCL Supports Cochlear Implantation for 30 Underprivileged Children in Maharashtradevdiscourse.com - July 4 at 9:36 AMFirst cochlear implant surgery performed in Laturuniindia.com - June 27 at 6:22 PMVanderbilt University Medical Center names CXObeckershospitalreview.com - June 27 at 1:22 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American TowerNYSE:AMTAmerican Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.CochlearOTCMKTS:CHEOFCochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.